Enzymatics: BRIEFQiagen cuts 2014 guidance on Enzymatics acquisition
has decided to take an acquisitionrelated pretax charge on operating income in q4 of 2014 of approximately $21 million
Read full article »
CEO
Enzymatics manufactures enzymes for molecular biology applications in the research and diagnostic markets.
Read more